Todd M. Hovis, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 100 Sweetbriar Dr, Columbus, TX 78934 Phone: 979-732-5771 Fax: 979-732-6922 |
Lori Jo Learned-burton, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 100 Sweetbriar Dr, Columbus, TX 78934 Phone: 979-732-5771 Fax: 979-732-6922 |
Arun G Nayar, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 100 Sweetbriar Dr, Columbus, TX 78934 Phone: 979-732-5771 Fax: 979-732-6922 |
Dr. John Perry Wooten, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 100 Sweetbriar Dr, Columbus, TX 78934 Phone: 817-702-1255 |
News Archive
Cumberland Pharmaceuticals Inc. announced today that an independently conducted study of Acetadote (acetylcysteine) Injection, or intravenous N-acetylcysteine, as a cost-saving treatment for acetaminophen poisoning was published in Volume 12, Number 4 of the peer-reviewed Journal of Medical Economics, distributed in December.
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that Tod Woolf, Ph.D., President and CEO, along with members of RXi's management team, will ring the Nasdaq closing bell tomorrow, Tuesday, Oct 6, 2009 at the Nasdaq Marketsite in New York City's Times Square.
A new study published in The Journal of Sexual Medicine reveals that several unhealthy lifestyle factors, such as weight problems, physical inactivity, high alcohol consumption, tobacco smoking, and hard drugs are associated with sexual dysfunctions in men. Additionally, an unhealthy lifestyle is more common in persons who are sexually inactive.
Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.
In order to develop more effective drugs against a range of cancers, researchers have been investigating the molecular structure of many diseased-linked enzymes in the body. An intriguing case in point is Taspase 1, a type of enzyme known as a protease.
› Verified 7 days ago